SNDX-5613

SNDX-5613 is a derivative of VTP-50469 (Cay-40759), an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1), also known as lysine methyltransferase 2A (KMT2A). It inhibits the growth of patient-derived acute myeloid leukemia (AML) cells expressing the gene encoding upstream binding factor (UBF) and containing tandem duplications (UBF-TDs) when UBF-TD-containing AML cells are co-cultured with mesenchymal stem cells. SNDX-5613 (50 mg/kg) reduces disease burden and improves survival when used alone and, to a greater extent, when used in combination with the CBP and p300 inhibitor GNE-781 (Cay-36450) in a MOLM-13 mouse xenograft model. It also reduces disease burden and increases survival in patient-derived xenograft (PDX) mouse models in which tumor cells contain rearrangements in the gene encoding KMT2A or mutations in the gene encoding nucleophosmin 1 (NPM1).Formal Name: N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-benzamide. CAS Number: 2169919-21-3. Synonyms: Revumenib. Molecular Formula: C32H47FN6O4S. Formula Weight: 630.8. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Soluble: >10 mg/ml, Ethanol: Soluble: >10 mg/ml. SMILES: CC(C)N(CC)C(C(C=C(C=C1)F)=C1OC2=CN=CN=C2N(C3)CC43CCN(C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)CC4)=O. InChi Code: InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3/t24-,26-. InChi Key: FRVSRBKUQZKTOW-YOCNBXQISA-N.